Evidence map›Paper›PMID 33753824›Full record

ArticleScientific reports2021

A surface plasmon resonance based approach for measuring response to pneumococcal vaccine.

Marta Garrido-Jareño, Leonor Puchades-Carrasco, Leticia Orti-Pérez, José Miguel Sahuquillo-Arce, María Del Carmen Meyer-García, Joan Mollar-Maseres, Carmina Lloret-Sos, Ana Gil-Brusola, José Luis López-Hontangas, José Manuel Beltrán-Garrido and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Marta Garrido-Jareño *Drug Discovery Unit, Health Research Institute La Fe, Valencia, Spain.
Leonor Puchades-Carrasco *Drug Discovery Unit, Health Research Institute La Fe, Valencia, Spain.
Leticia Orti-PérezDrug Discovery Unit, Health Research Institute La Fe, Valencia, Spain.
José Miguel Sahuquillo-ArceMicrobiology Department, University and Polytechnic Hospital La Fe, Valencia, Spain.
María Del Carmen Meyer-GarcíaPreventive Medicine Department, University and Polytechnic Hospital La Fe, Valencia, Spain.
Joan Mollar-MaseresPreventive Medicine Department, University and Polytechnic Hospital La Fe, Valencia, Spain.
Carmina Lloret-SosMicrobiology Department, University and Polytechnic Hospital La Fe, Valencia, Spain.
Ana Gil-BrusolaMicrobiology Department, University and Polytechnic Hospital La Fe, Valencia, Spain.
José Luis López-HontangasMicrobiology Department, University and Polytechnic Hospital La Fe, Valencia, Spain.
José Manuel Beltrán-GarridoPreventive Medicine Department, University and Polytechnic Hospital La Fe, Valencia, Spain.
Javier Pemán-GarcíaMicrobiology Department, University and Polytechnic Hospital La Fe, Valencia, Spain. peman_jav@gva.es.
Antonio Pineda-LucenaDrug Discovery Unit, Health Research Institute La Fe, Valencia, Spain. apinedal@unav.es.
Hospital Universitari i Politècnic La Fe · ESLeitat Technological Center · ESUniversidad de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Incidence of pneumococcal disease has increased worldwide in recent years. Response to pneumococcal vaccine is usually measured using the multiserotype enzyme-linked immunosorbent assay (ELISA) pneumococcal test. However, this approach presents several limitations. Therefore, the introduction of new and more robust analytical approaches able to provide information on the efficacy of the pneumococcal vaccine would be very beneficial for the clinical management of patients. Surface plasmon resonance (SPR) has been shown to offer a valuable understanding of vaccines' properties over the last years. The aim of this study is to evaluate the reliability of SPR for the anti-pneumococcal capsular polysaccharides (anti-PnPs) IgGs quantification in vaccinated. Fast protein liquid chromatography (FPLC) was used for the isolation of total IgGs from serum samples of vaccinated patients. Binding-SPR assays were performed to study the interaction between anti-PnPs IgGs and PCV13. A robust correlation was found between serum levels of anti-PnPs IgGs, measured by ELISA, and the SPR signal. Moreover, it was possible to correctly classify patients into "non-responder", "responder" and "high-responder" groups according to their specific SPR PCV13 response profiles. SPR technology provides a valuable tool for reliably characterize the interaction between anti-PnPs IgGs and PCV13 in a very short experimental time.

Indexed as

Immunogenicity, VaccineAdultHumansImmunoglobulin GMiddle AgedPneumococcal VaccinesSurface Plasmon Resonance13-valent pneumococcal vaccineImmunoglobulin GPneumococcal Vaccines

Identifiers

PMID33753824
PMCPMC7985148
OpenAlexW3137012531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.